Summary & Overview
HCPCS M0220: Tixagevimab and Cilgavimab Injection for Pre-Exposure Prophylaxis
HCPCS Level II code M0220 designates the injection of tixagevimab and cilgavimab for pre-exposure prophylaxis against SARS‑CoV‑2 in eligible individuals, including the injection and post-administration monitoring. This code matters nationally as monoclonal antibody prophylaxis remains a treatment option for people with moderate to severely compromised immune systems and for those with contraindications to available COVID‑19 vaccines. Billing clarity for M0220 affects access to prophylactic therapy and consistent coverage across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical indication and service context for M0220, payer coverage considerations, common billing modifiers, and typical sites of service. The publication summarizes policy-relevant points that influence reimbursement and coding accuracy, highlights clinical context for eligible patient populations, and notes where input data is not available. This resource is intended to support billing teams, clinicians, and policy stakeholders seeking a national perspective on coding and coverage for monoclonal antibody pre-exposure prophylaxis.
Billing Code Overview
HCPCS Level II code M0220 describes the administration of tixagevimab and cilgavimab as a single service for pre-exposure prophylaxis against SARS‑CoV‑2 for certain adults and pediatric patients (ages 12 and older, weighing at least 40 kg). The description covers the injection itself and the required post-administration monitoring period.
-
Service Type: Monoclonal antibody injection for COVID-19 pre-exposure prophylaxis
-
Typical Site of Service: Outpatient clinic, infusion center, physician office, pharmacy-based clinic, or other ambulatory care settings where injections and post-administration monitoring are provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent (age ≥12 years and weight ≥40 kg) with either moderate to severe immunocompromise or a documented history of severe allergic reaction to a COVID-19 vaccine or vaccine component, presenting for pre-exposure prophylaxis against SARS‑CoV‑2. The patient is scheduled for administration of M0220 (tixagevimab and cilgavimab) in an outpatient infusion clinic, primary care office, ambulatory infusion suite, or community pharmacy that offers long‑acting monoclonal antibody prophylaxis. Clinical workflow: the patient arrives for a pre‑scheduled appointment, identification and consent are confirmed, a brief pre‑administration assessment (vital signs, review of allergies, medication list, and current symptoms) is completed, and documentation of indication (immunocompromised status or vaccine contraindication) is verified in the chart. The injection is administered intramuscularly per product instructions, the encounter includes post‑administration monitoring for adverse reactions (observation period typically 15–30 minutes), and the injection and monitoring are documented in the medical record. Billing uses M0220 to represent the drug administration and included monitoring; applicable facility and professional claims may append modifiers for special circumstances such as increased procedural complexity, anesthesia, or bilateral procedures when relevant. Medication reconciliation, adverse event counseling, and scheduling of follow‑up or repeat dosing per current clinical guidance are completed before discharge.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|